Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 6 | 2022 | 357 | 1.830 |
Why?
|
| Pneumonectomy | 3 | 2019 | 10 | 1.620 |
Why?
|
| Thoracotomy | 2 | 2019 | 17 | 1.080 |
Why?
|
| Lymph Node Excision | 2 | 2019 | 101 | 1.070 |
Why?
|
| Lung Diseases | 2 | 2018 | 43 | 0.980 |
Why?
|
| Bronchoscopy | 2 | 2024 | 35 | 0.930 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 105 | 0.860 |
Why?
|
| Thoracic Surgery | 1 | 2024 | 14 | 0.860 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 51 | 0.820 |
Why?
|
| Hernia, Hiatal | 1 | 2019 | 4 | 0.640 |
Why?
|
| Herniorrhaphy | 1 | 2019 | 17 | 0.630 |
Why?
|
| Esophagectomy | 2 | 2016 | 9 | 0.590 |
Why?
|
| Esophageal Neoplasms | 2 | 2016 | 32 | 0.570 |
Why?
|
| Empyema, Pleural | 1 | 2018 | 3 | 0.570 |
Why?
|
| Chest Tubes | 1 | 2018 | 9 | 0.570 |
Why?
|
| Drainage | 1 | 2018 | 45 | 0.560 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2017 | 3 | 0.550 |
Why?
|
| Myotomy | 1 | 2017 | 5 | 0.550 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2017 | 9 | 0.550 |
Why?
|
| Esophageal Achalasia | 1 | 2017 | 6 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 244 | 0.490 |
Why?
|
| Metastasectomy | 1 | 2016 | 6 | 0.490 |
Why?
|
| Laparoscopy | 1 | 2017 | 156 | 0.480 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2014 | 10 | 0.450 |
Why?
|
| ErbB Receptors | 2 | 2011 | 100 | 0.410 |
Why?
|
| Electromagnetic Phenomena | 2 | 2024 | 15 | 0.400 |
Why?
|
| Postoperative Complications | 1 | 2018 | 631 | 0.400 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 300 | 0.340 |
Why?
|
| ras Proteins | 1 | 2011 | 43 | 0.340 |
Why?
|
| Humans | 13 | 2024 | 28581 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 140 | 0.320 |
Why?
|
| Mutation | 2 | 2011 | 864 | 0.320 |
Why?
|
| Prognosis | 3 | 2019 | 807 | 0.300 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2045 | 0.290 |
Why?
|
| Retrospective Studies | 4 | 2022 | 2612 | 0.290 |
Why?
|
| African Americans | 1 | 2011 | 352 | 0.290 |
Why?
|
| Aged | 5 | 2018 | 5525 | 0.220 |
Why?
|
| Biopsy | 1 | 2024 | 207 | 0.200 |
Why?
|
| Male | 7 | 2018 | 13771 | 0.190 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 478 | 0.190 |
Why?
|
| Adult | 5 | 2018 | 7922 | 0.190 |
Why?
|
| Middle Aged | 4 | 2018 | 7310 | 0.190 |
Why?
|
| Female | 6 | 2018 | 15471 | 0.170 |
Why?
|
| Survival Rate | 2 | 2019 | 431 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 132 | 0.170 |
Why?
|
| Young Adult | 2 | 2018 | 2804 | 0.160 |
Why?
|
| Adolescent | 2 | 2018 | 3165 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2017 | 2402 | 0.160 |
Why?
|
| Esophagus | 1 | 2019 | 70 | 0.150 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 77 | 0.150 |
Why?
|
| Fundoplication | 1 | 2017 | 4 | 0.140 |
Why?
|
| Esophagoscopy | 1 | 2017 | 16 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2018 | 108 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2018 | 107 | 0.130 |
Why?
|
| Intraoperative Period | 1 | 2016 | 21 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 126 | 0.120 |
Why?
|
| Esophageal Diseases | 1 | 2015 | 13 | 0.120 |
Why?
|
| Models, Anatomic | 1 | 2015 | 25 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 13 | 0.120 |
Why?
|
| Forced Expiratory Volume | 1 | 2015 | 17 | 0.120 |
Why?
|
| Printing, Three-Dimensional | 1 | 2015 | 31 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 163 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2015 | 76 | 0.110 |
Why?
|
| Patient Selection | 1 | 2015 | 149 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2015 | 622 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 34 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 61 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 270 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2009 | 1 | 0.080 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2009 | 6 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2011 | 893 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 453 | 0.070 |
Why?
|
| Minnesota | 1 | 2016 | 42 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 68 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1026 | 0.030 |
Why?
|
| Genes, ras | 1 | 2009 | 12 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 35 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 37 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2009 | 77 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 75 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 126 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 137 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 194 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 233 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 465 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2009 | 815 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 1338 | 0.010 |
Why?
|